Meeting
2015 ASCO Annual Meeting
Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity.
Authors
Narendiran Rajasekaran
Center for Clinical Sciences Research Stanford, Stanford, CA
Narendiran Rajasekaran , Suparna Dutt , Aurelien Marabelle , Roch Houot , Mohith Sadaram , Johnathan Hebb , Idit Sagiv-Barfi , Sid Ambulkar , Amanda Sandamali Rajapaksa , Cariad Chester , Erin Waller , Holbrook Edwin Kohrt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3075)
DOI
10.1200/jco.2015.33.15_suppl.3075
Abstract #
3075
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.
First Author: Sean David Reiff
Poster
2020 ASCO Virtual Scientific Program
Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab.
First Author: Paola Ghione
Poster
2024 ASCO Annual Meeting
Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.
First Author: Olivier Demaria
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Therapeutic effects of 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody in combination with expanded natural killer cells against rituximab sensitive and resistant Burkitt lymphoma (BL).
First Author: Yaya Chu